PET/CT imaging of c-Myc transgenic mice identifies the genotoxic N-Nitroso-Diethylamine as carcinogen in a Short-Term cancer bioassay

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hueper, Katja ^a   Elalfy, Mahmoud ^b   Laenger, Florian ^a   Halter, Roman ^b   Rodt, Thomas ^a   Galanski, Michael ^a   Borlak, Juergen ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYLCRESOL; CARCINOGEN; DIETHYLNITROSAMINE; PARACETAMOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENOTOXICITY; GLUCOSE METABOLISM; HISTOPATHOLOGY; IMAGE ANALYSIS; IN VIVO STUDY; LIVER CANCER; LIVER STRUCTURE; LUNG CANCER; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; POSITRON EMISSION TOMOGRAPHY; SHORT COURSE THERAPY;

ANIMALS; CARCINOGENS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DIETHYLNITROSAMINE; GLUCOSE; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR BURDEN;

ANIMALIA; MUS MUSCULUS;

EID: 84856434585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030432     Document Type: Article

References (41)

1. Bucher JR, Portier C, (2004) Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals. Toxicological Sciences 82: 363-366.
2. Cohen SM, (2010) Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Toxicologic Pathology 38: 487-501.
3. Cohen SM, Klaunig J, Meek ME, Hill RN, Pastoor T, et al. (2004) Evaluating the human relevance of chemically induced animal tumors. Toxicological Sciences 78: 181-186.
4. Darvasi A, (1998) Experimental strategies for the genetic dissection of complex traits in animal models. Nature Genetics 18: 19-24.
5. MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, et al. (2004) The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicological Sciences 77: 188-194.
6. Pritchard JB, French JE, Davis BJ, Haseman JK, (2003) The role of transgenic mouse models in carcinogen identification. Environmental Health Perspectives 111: 444-454.
7. Rohrbeck A, Salinas G, Maaser K, Linge J, Salovaara S, et al. (2010) Toxicogenomics Applied to In Vitro Carcinogenicity Testing with Balb/c 3T3 Cells Revealed a Gene Signature Predictive of Chemical Carcinogens. Toxicological Sciences 118: 31-41.
8. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM, (2008) Experimental models of hepatocellular carcinoma. Journal of Hepatology 48: 858-879.
9. Iatropoulos MJ, Jeffrey AM, Schluter G, Enzmann HG, Williams GM, (2001) Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53-deficient (+/-) and wild type (+/+) mice. Archives of Toxicology 75: 52-58.
10. Arai T, Ogawa T, Nakamura M, Hosoya M, Ohnishi Y, (2002) Changes in hepatic enzyme activities in transgenic mice carrying human prototype c-Ha-ras gene treated with diethylnitrosamine. The Journal of Veterinary Medical Science 64: 1065-1067.
11. Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, et al. (1996) Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17: 2455-2461.
12. Yamamoto S, Urano K, Nomura T, (1998) Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicology Letters 102-103: 473-478.
13. Almajdub M, Nejjari M, Poncet G, Magnier L, Chereul E, et al. (2007) In-vivo high-resolution X-ray microtomography for liver and spleen tumor assessment in mice. Contrast Media & Molecular Imaging 2: 88-93.
14. Dalemans W, Perraud F, Le Meur M, Gerlinger P, Courtney M, et al. (1990) Heterologous protein expression by transimmortalized differentiated liver cell lines derived from transgenic mice (hepatomas/alpha 1 antitrypsin/ONC mouse). Biologicals 18: 191-198.
15. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE, (2010) Targeting c-Myc as a novel approach for hepatocellular carcinoma. World Journal of Hepatology 2: 16-20.
16. Bag S, Schambach SJ, Boll H, Schilling L, Groden C, et al. (2010) Current concepts for experimental micro-CT in small animals. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 182: 390-403.
17. Martiniova L, Schimel D, Lai EW, Limpuangthip A, Kvetnansky R, et al. (2010) In vivo micro-CT imaging of liver lesions in small animal models. Methods (San Diego, Calif) 50: 20-25.
18. von Falck C, Rodt T, Halter R, Spanel R, Galanski M, et al. (2009) Combined microPET/CT for imaging of hepatocellular carcinoma in mice. Frontiers in Bioscience 14: 2193-2202.
19. Weber SM, Peterson KA, Durkee B, Qi C, Longino M, et al. (2004) Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy is dependent on adequate contrast enhancement. The Journal of Surgical Research 119: 41-45.
20. Witschi HP, Hakkinen PJ, Kehrer JP, (1981) Modification of lung tumor development in A/J mice. Toxicology 21: 37-45.
21. Ulland BM, Weisburger JH, Yamamoto RS, Weisburger EK, (1973) Antioxidants and carcinogenesis: butylated hydroxytoluene, but not diphenyl-p-phenylenediamine, inhibits cancer induction by N-2-fluorenylacetamide and by N-hydroxy-N-2-fluorenylacetamide in rats. Food and Cosmetics Toxicology 11: 199-207.
22. Weisburger EK, Evarts RP, (1977) Inhibitory effect of butylated hydroxytoluene (BHT) on intestinal carcinogenesis in rats by azoxymethane. Food and Cosmetics Toxicology 15: 139-141.
23. Shaarawy SM, Tohamy AA, Elgendy SM, Elmageed ZY, Bahnasy A, et al. (2009) Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. International Journal of Biological Sciences 5: 549-557.
24. Song HS, Kim HR, Park TW, Cho BJ, Choi MY, et al. (2009) Antioxidant Effect of CoQ(10) on N-nitrosodiethylamine-induced Oxidative Stress in Mice. The Korean Journal of Physiology & Pharmacology 13: 321-326.
25. Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, et al. (2007) Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Research 67: 9844-9851.
26. Thapliyal R, Naresh KN, Rao KV, Maru GB, (2003) Inhibition of nitrosodiethylamine-induced hepatocarcinogenesis by dietary turmeric in rats. Toxicology Letters 139: 45-54.
27. Contrera JF, DeGeorge JJ, (1998) In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Perspect 106 (Suppl 1): 71-80.
28. Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, et al. (2000) Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol 28: 482-499.
29. Vries de A, Steeg Hv, Opperhuizen A, (2004) Transgenic mice as alternatives in carcinogenicity testing: current status. RIVM report 340700001/2004.
30. Henning T, Weber AW, Bauer JS, Meier R, Carlsen JM, et al. (2008) Imaging characteristics of DHOG, a hepatobiliary contrast agent for preclinical microCT in mice. Academic Radiology 15: 342-349.
31. Badea CT, Drangova M, Holdsworth DW, Johnson GA, (2008) In vivo small-animal imaging using micro-CT and digital subtraction angiography. Physics in Medicine and Biology 53: R319-350.
32. Suckow CE, Stout DB, (2008) MicroCT liver contrast agent enhancement over time, dose, and mouse strain. Molecular imaging and biology 10: 114-120.
33. Santoni-Rugiu E, Nagy P, Jensen MR, Factor VM, Thorgeirsson SS, (1996) Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. The American journal of Pathology 149: 407-428.
34. Finnberg N, Stenius U, Hogberg J, (2004) Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice. Cancer Letters 207: 149-155.
35. Usui T, Mutai M, Hisada S, Takoaka M, Soper KA, et al. (2001) CB6F1-rasH2 mouse: overview of available data. Toxicologic Pathology 29 (Suppl): 90-108.
36. Lok E, Mehta R, Jee P, Laver G, Nera EA, et al. (1995) The effect of butylated hydroxytoluene on the growth of enzyme-altered foci in male Fischer 344 rat liver tissue. Carcinogenesis 16: 1071-1078.
37. Witschi HP, (1986) Enhanced tumour development by butylated hydroxytoluene (BHT) in the liver, lung and gastro-intestinal tract. Food and chemical toxicology 24: 1127-1130.
38. Witschi HR, Morse CC, (1983) Enhancement of lung tumor formation in mice by dietary butylated hydroxytoluene: dose-time relationships and cell kinetics. Journal of the National Cancer Institute 71: 859-866.
39. Gressani KM, Leone-Kabler S, O'Sullivan MG, Case LD, Malkinson AM, et al. (1999) Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis 20: 2159-2165.
40. Fukushima S, Kinoshita A, Puatanachokchai R, Kushida M, Wanibuchi H, et al. (2005) Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens. Carcinogenesis 26: 1835-1845.
41. Thompson JA, Schullek KM, Fernandez CA, Malkinson AM, (1989) A metabolite of butylated hydroxytoluene with potent tumor-promoting activity in mouse lung. Carcinogenesis 10: 773-775.